1
项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的临床试验A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years
Animal and human studies have shown that the prime-boost immunization strategy using malaria antigens expressed in plasmid or viral vectors induces strong cellular immune responses. An immunization regimen with the malaria vaccines DNA ME-TRAP followed by MVA ME-TRAP induced strong T cell responses in adults in the United Kingdom (UK) and in the Gambia but did not provide significant clinical protection against infection. The investigators assessed two new vaccines which utilize a similar immunization strategy but a different malaria antigen, a circumsporozoite (CS) protein. The entire CS protein was expressed either in a modified vaccinia virus Ankara (MVA) CS, or an attenuated fowlpox virus strain (FP9) CS.
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的临床结果
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的转化医学
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的专利(医药)
1
项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的文献(医药)2006-10-01·Vaccine3区 · 医学
Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men
3区 · 医学
Article
作者: T. Lang ; P. Milligan ; M.A. Skinner ; S. Keita ; E.B. Imoukhuede ; J. Ismaili ; S. Todryk ; S.M. Laidlaw ; M. Sowe ; D. Nwakanma ; B.M. Greenwood ; T. Berthoud ; K. Bojang ; F. Njie ; S. Keating ; S. Gilbert ; A.V.S. Hill
We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodium falciparum circumsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines.
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的药物交易